Ketorolac

Ketorolac acid · 5-benzoyl-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid · Fluoxetin · Acular · (S)-Ketorolac · Dolac · rs37619 · Lixidol

https://huagongshe.com/ko/chemical/3826

식별자 및 물리적 특성

CAS No.	66635-83-4
분자식	C15H13NO3
평균 분자량	255.27 g/mol
단동위원소 질량	255.08954328 g/mol
SMILES	O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
InChIKey	OZWKMVRBQXNZKK-UHFFFAOYSA-N
PubChem CID	3826
ChEMBL	CHEMBL469
ChEBI	CHEBI:6129
EC No.	616-049-1
DTXSID	DTXSID8023189

화학 및 물리적 성질

XLogP	1.9
극성 표면적	59.3
수소 결합 공여자 수	1
수소 결합 수용자 수	3
회전 가능 결합 수	3
무거운 원자 수	19
형식 전하	0
복잡도	376
의약품	PharmaceuticalsPharmaceuticals -> Analgesics and anti-inflammatories
LogP(분배 계수)	2.12.72
용해도	5.13e-01 g/L클로로포름(약간 용해됨), 메탄올(약간 용해됨)
Human Drugs	Breast FeedingLactationMilk, HumanAnalgesic AgentsAnti-inflammatory Agents, NonsteroidalPharmaceuticals
녹는점	162-165 °C (tromethamine salt)165 - 167 °C (tromethamine salt)160-161°C
Physical Description	Solid
Dissociation Constants	3.493.5
끓는 점	493.2±40.0 °C(Predicted)
밀도	1.33±0.1 g/cm3(Predicted)
저장 조건	2-8°C
물리적 상태	고체
pKa(산도 계수)	3.49 ±0.02(at 25℃)
색상	회백색
용해도	183mg/L(32℃)
InChI	InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
InChIKey	OZWKMVRBQXNZKK-UHFFFAOYSA-N
SMILES	N12CCC(C(O)=O)C1=CC=C2C(=O)C1=CC=CC=C1
EPA	1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro- (74103-06-3)

화학적 성질

Light yellow solid

안전 및 규제

GHS 분류	DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 7 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
규제 정보	Status: Active Update: 24-10-2017 https://echa.europa.eu/registration-dossier/-/registered-dossier/19373
Hazard Classes and Categories	Acute Tox. 3 (100%)
Hepatotoxicity	Prospective studies show that up to 1% of patients taking ketorolac experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations above 3 times the upper limit of normal (ULN) occur in less than 1% of patients. Clinically apparent liver injury with jaundice from ketorolac has not been described in any detail so that the latency, clinical features and prognosis of injury is unknown. Ketorolac is not mentioned as an etiologic agent in large case series on drug induced liver injury or acute liver failure from the United States. However, the antiplatelet activity of ketorolac can lead to complications mostly due to platelet dysfunction and bleeding, and several instances of hepatic rupture and subcapsular hepatic hematomas have been reported with its use which might present clinically as acute liver injury.
유해 작용	Drug-Drug Interactions
독성 요약	High quantities or prolonged use of ketorolac can lead to hepatotoxicity and nephrotoxicity. In addition, ketorolac can cause multiple skin disorders, such as toxic epidermal necrolysis. Anaphylactic shock has been characterized due to ketorolac overdose.
Drug Induced Liver Injury	Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)ketorolacToradol®NSAIDs3less-DILI-concern drugs
Effects During Pregnancy and Lactation	◉ Summary of Use during Lactation

용도

antiarrhythmic

일반 설명

Ketorolac tromethamine (Toradol), marketed as a mixture of(R)- and (S)-ketorolac enantiomers, is a potent NSAID analgesicindicated for the treatment of moderately severe, acutepain. It should be noted that the pharmacokinetic dispositionof ketorolac in humans is subject to marked enantioselectivity.Thus, it is important to monitor the individual blood levelsso an accurate assessment of its therapeutic action can bemade correctly. However, it should be noted that, beingone of the conventional NSAIDs with highest risk of GIcomplications, its administration should not exceed 5 days.